The Multifaceted Patient Burden and Drivers of Disease in Prurigo Nodularis

In this episode, Dr. Sarina Elmariah and Dr. Brian Kim explore prurigo nodularis (PN), with a focus on severe itch, fibrotic skin lesions, and their impact on patients’ quality of life. They discuss PN epidemiology, common comorbidities, and the challenges of managing multimorbid patients, while breaking down the neuroimmune mechanisms, highlighting the role of type 2 cytokines in itch and lesion development. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Sarina Elmariah, MD, PhD, MPH has the following interests to disclose: Consultant, advisor, or investigator: Bambusa Therapeutics, Celldex, Disc Medicine, Galderma, Incyte, Novartis, Pfizer, Regeneron, Sanofi, ZenZema Brian Kim, MD, is co-founder of Alys Pharmaceuticals and Neurommune Therapeutics; he has served as a consultant for ABRAX Japan, AbbVie, Amgen, Attovia Therapeutics, Eli Lilly and Company, Evommune, Galderma, Gilead, LEO Pharma, Neurocrine, Novartis, Pfizer, Recens Medical, Regeneron, Sanofi, Septerna, Triveni Bio; he has stock in ABRAX Japan, Alys Pharamaceuticals, Attovia Therapeutics, Locus Biosciences, Neurommune Therapeutics, Recens Medical, and Triveni Bio. © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2504334 – 1.0 – 05/2026 MAT-US-2604824 v1.0 - P Expiration Date: 05/4/2028